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Stroke Scale (NIHSS) and lymphocytopenia on admission (LOA) were strongly associated with subsequent infection and thus potentially outcome. 9, 10 Yet, a substantial proportion of patients without initial lymphocytopenia develop lymphocytopenia during course of disease. 10 These patients may represent a subgroup of patients potentially benefitting from immunomodulatory treatment approaches. 11 This study investigated for the first time in a large cohort of solely ICH patients (1) the natural course of lymphocytopenia, (2) parameters associated with LOA and during hospital stay, and (3) evaluated the clinical impact of lymphocytopenia both on admission and during clinical course on mortality and functional outcome.
Methods
Patient Selection
We analyzed all consecutive patients with spontaneous ICH admitted to the Department of Neurology between 2006 and 2014. We did not consider secondary ICH, that is, ICH related to trauma, tumor, arteriovenous malformations, central venous thrombosis, subarachnoid hemorrhage, or thrombolysis. Moreover, we did not consider patients receiving permanent immunomodulatory treatment-for example, consisting of corticosteroids, methotrexate, other cytostatic drugs and biologicals, such as monoclonal antibodies-before admission. Altogether, we identified 960 patients with ICH of whom 105 patients had no follow-up data available or refused consent. Hence, 855 patients remained for final analysis.
Parameter Acquisition
As described previously, 12 we retrieved data of all patients from our institutional prospective database. We reviewed data for demographics, medical history, imaging, and in-hospital parameters (Glasgow Coma Scale [GCS] , NIHSS, ICH score, blood pressure, mechanical ventilation, length of stay, external ventricular drainage for hydrocephalus, diagnosis of pneumonia, urinary tract infection, and sepsis according to established criteria). [13] [14] [15] Laboratory parameters were retrieved from our institutional database and we investigated those We assessed patient characteristics, for example, history of stroke, cardiovascular comorbidity, nicotine or alcohol abuse, by standardized mailed questionnaires. We conducted a semiquantitative phone interviews-performed by physicians trained and certified for data collection on disability and quality of life-with patients or their closest relatives if the questionnaire did not return within 2 to 4 weeks. 12 We contacted primary care physicians only in cases of insufficient data retrieval.
Outcome Measures
We obtained data on mortality and functional outcome as described above. Functional outcome was evaluated using the modified Rankin scale (mRS) on day 90 after stroke onset. We defined favorable outcome as mRS score of 0 to 3 and unfavorable outcome as mRS score of 4 to 6.
Imaging
As described previously, 12 we diagnosed ICH by computed tomography or magnetic resonance imaging. Two neuroradiologists (H.L. and S.K.) blinded to clinical data reviewed the scans independently and in cases of discrepancies a second consensus analysis was made. We calculated ICH volume according to the ABC/2-formula, and ABC/3-formula, respectively, in irregularly shaped ICH. [19] [20] [21] Hematoma enlargement was scored in cases with an increase in volume >33% 22 on follow-up imaging. The amount of intraventricular hematoma was scored using Graeb score summation.
Statistical Analysis
We used the statistical software package SPSS 20.0 (www.spss etc.). The significance level was set at α=0.05 and statistical tests were 2 sided. We used the Kolmogorov-Smirnov test to determine the distribution of data. Data are presented as mean±SD (compared using the student t test), or as median and interquartile range (compared using the Mann-Whitney U test), as appropriate. We used the Pearson χ 2 and the Fisher exact tests to compare frequency distributions of categorized variables between patients with and without LOA and during clinical course. To identify parameters independently associated with outcome, we calculated step-wise forward inclusion multivariate logistic regression models including parameters showing a statistical trend (P<0.1) in univariate testing. To explore associations of clinical parameters with the presence of lymphocytopenia, we performed receiver operating characteristics curve analyses. 
Results
LOA: Prevalence, Related Factors, and Outcome
The prevalence of LOA in the entire cohort was 233 of 855 (27.3%). Parameters associated with LOA were predominantly the neurological status on admission as well as baseline imaging findings (Table 1) . Patients with LOA had a median GCS of 11 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and a median hemorrhage volume of 18.5 mL (6. Figure 1 ).
Lymphocytes Concentration Over Time
The median lymphocyte count of the entire cohort was 1.4 (0.94-2.05 [10 9 /L]) on admission. Figure 2 displays the natural course of lymphocytes count during hospital stay ( Figure I in the online-only Data Supplement for course of neutrophile granulocytes, monocytes, and leucocytes). The nadir in lymphocyte count was 1.1 (0.80-1.53 [10 9 /L]) evident at day 5. Characteristics of patients with lymphocytopenia on day 5 as compared with patients without lymphocytopenia on day 5 are shown in Table 2 . Patients with lymphocytopenia on day 5 were significantly older, presented with higher NIHSS and larger hematoma volumes on admission and suffered more frequently from intraventricular hematoma ( Table 2 ). Both development of pneumonia and sepsis were significantly more often in patients with day-5-lymphocytopenia compared with patients without day-5-lymphocytopenia (P=0.003 and P=0.001; Table 2 ). Both mortality and the proportion of patients with unfavorable functional outcome at 3 months were significantly higher in patients with day-5-lymphocytopenia (mortality: 38.3% versus 14.8%, P<0.001; outcome: mRS, 4-6: 83.9% versus 58.4%, P<0.001).
Comparison of Patients With LOA and Day-5-Lymphocytopenia
Given a nadir of lymphocyte count at day 5, we compared patients with LOA and day-5-lymphocytopenia. On day 5, 193 patients showed lymphocytopenia. Of these, however, 105 were already in the group of patients with on-admission lymphocytopenia. Thus, 88 patients (who showed no lymphocytopenia on admission) developed lymphocytopenia between admission and day 5 ( 
Clinical Significance of LOA and Day-5-Lymphocytopenia
These findings were supported by receiver operating characteristics analyses exploring the clinical impact of LOA and day-5-lymphocytopenia on unfavorable functional outcome ( Figure 3) . Receiver operating characteristics curve analysis confirmed a cutoff for LOA≥0.745 (10 9 /L) and for day-5-lymphocytopenia≥1.005 (10 9 /L) for optimal discrimination between good and unfavorable outcome, providing evidence that day-5-lymphocytopenia is more relevant to outcome than LOA (LOA: area under the curve=0.513, P=0.676, Youden's index=0.084; day-5-lymphocytopenia: area under the curve=0.673, P<0.0001, Youden's index=0.290; Figure 3 ). Given the baseline differences in age, clinical status, and hematoma volume among patients with LOA and day-5-lymphocytopenia (Table 2) , to minimize baseline confounding, we investigated the associations of age and ICH volume with day-5-lymphocytopenia. Receiver operating characteristics analyses revealed the absence of a true positive and accurate association of neither age nor hematoma volume with day-5-lymphocytopenia (age and day-5-lymphocytopenia: area under the curve=0.540, P=0.198, Youden's index=0.106; volume and day-5-lymphocytopenia: area under the curve=0.550, P=0.0898, Youden's index=0.1224). In addition, we performed multivariate logistic regression models-adjusted for those parameters established to influence outcome after ICH-to identify parameters associated with unfavorable outcome. Model 1 included LOA and model 2 included day-5-lymphocytopenia as independent variables (Table II in 
Clinical Impact of Permanent Lymphocytopenia
In the final step, we compared patients with both LOA and day-5-lymphocytopenia with those patients with absent lymphocytopenic conditions both on admission and on day 5 (Table III in the online-only Data Supplement). Patients without any lymphocytopenia were younger, had less severe ICH, developed fewer infections, and showed both reduced rates of mortality and fewer rates of unfavorable functional outcome.
Discussion
This study for the first time systematically investigated the clinical course and clinical impact of lymphocytopenia in patients with ICH. As key findings, patients with lymphocytopenia-as compared with patients without lymphocytopenia-were older, clinically more severely affected and showed worse outcome. Of note, lymphocytopenia that developed during clinical course seems to represent an even worse condition than LOA. Several aspects emerge from the data.
Lymphocytopenia has been described in the context of stroke-induced immunosuppression syndrome, which usually is accompanied with monocyte dysfunction and which is associated with increased susceptibility to bacterial infections.
3-7 Development of stroke-induced immunosuppression syndrome was reported to depend on lesion size and was mainly observed after large ischemic stroke. 8 Inflammatory mechanisms participating in ICH may result in inflammatory markers on admission, such as fever, elevated white blood cell count, interleukin-6, and fibrinogen which are associated with unfavorable outcome. 9, 10 In line with previous reports, our data support that lymphocytopenia is a frequent condition in patients with ICH and is related both to increased rates of infection and to unfavorable outcome. Do these data reflect a causal relationship? At first glance, it seems unlikely that lymphocytopenia may account for the described findings. This is mainly because of the fact that immunocompetence is not solely based on lymphocyte count. According to various investigations, the presence of sufficient neutrophiles in combination with preexisting humoral competence basically should prevent overwhelming infectious reactions. 6, 23, 24 Hence, to address whether lymphycytopenia causally affected outcome in our cohort, we statistically minimized possible bias and found a significant association of developing lymphocytopenia on outcome that was unrelated to baseline confounders, such as age and hematoma volume. Being aware that these associations still may reflect an epiphenomenon of variables and a bias in terms of comorbidity, a subset of patients with ICH-that is, those patients without LOA who develop lymphocytopenia-however, may represent a high-risk population potentially benefitting from pharmacological interventions. 3, [25] [26] [27] [28] Such therapeutical approaches may include intensified screening for infections and more liberal use of anti-infective agents. 29, 30 Given various limitations of this study, above findings need to be interpreted with caution. Given that this study lacks a prospective design without specific blood sampling analyses and regimens for diagnosis and treatment of infections weakens the significance of reported associations. Further outcome analyses were based on individual self-reporting rather than on objectively blinded outcome assessment. Although we accounted for methodological shortcomings by minimizing statistical bias, findings of this study may still overestimate both causal and clinically significant associations. Both issues, whether lymophocytopenia indeed independently affects outcome and-if so-pharmacological interventions might result in a clinical net benefit, need to be investigated in future studies. Suppl. 
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